Xiaozhen Xie

Array ( [id] => 17898406 [patent_doc_number] => 20220308068 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => BIOMARKER IN OSTEOPOROSIS INTERVENTION THERAPY BY BONE PEPTIDE, SCREENING METHOD AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/310842 [patent_app_country] => US [patent_app_date] => 2020-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9700 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17310842 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885425 [patent_doc_number] => 20210171620 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => ANTIBODIES NEUTRALIZING GM-CSF FOR USE IN THE TREATMENT OF RHEUMATOID ARTHRITIS OR AS ANALGESICS [patent_app_type] => utility [patent_app_number] => 16/995617 [patent_app_country] => US [patent_app_date] => 2020-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44910 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16995617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17850558 [patent_doc_number] => 20220280599 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => HLA-DR/CII PEPTIDE COMPLEXES FOR TREATING ARTHRITIS [patent_app_type] => utility [patent_app_number] => 17/633894 [patent_app_country] => US [patent_app_date] => 2020-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23970 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17633894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16791754 [patent_doc_number] => 20210121571 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => METHODS OF REDUCING AGGREGATION OF IL-1RA [patent_app_type] => utility [patent_app_number] => 16/945494 [patent_app_country] => US [patent_app_date] => 2020-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16945494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17830128 [patent_doc_number] => 20220267432 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => METHOD FOR TREATING AUTOIMMUNE DISEASE BY IL-17 ANTAGONIST [patent_app_type] => utility [patent_app_number] => 17/631289 [patent_app_country] => US [patent_app_date] => 2020-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6692 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17631289 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612215 [patent_doc_number] => 20210030868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => FORMULATION OF ANTIBODY BASED DRUGS FOR TREATING LUNG CANCER BY INHALATION [patent_app_type] => utility [patent_app_number] => 16/942339 [patent_app_country] => US [patent_app_date] => 2020-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4843 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16942339 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16541002 [patent_doc_number] => 20200407415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => ACTIVIN RECEPTOR TYPE IIB VARIANTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/924473 [patent_app_country] => US [patent_app_date] => 2020-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32151 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16924473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16854927 [patent_doc_number] => 20210155672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING INEFFECTIVE ERYTHROPOIESIS [patent_app_type] => utility [patent_app_number] => 16/919377 [patent_app_country] => US [patent_app_date] => 2020-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16919377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16613955 [patent_doc_number] => 20210032608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGR3) POLYPEPTIDE FOR USE IN THE PREVENTION OR TREATMENT OF SKELETAL GROWTH RETARDATION DISORDERS [patent_app_type] => utility [patent_app_number] => 16/906046 [patent_app_country] => US [patent_app_date] => 2020-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16906046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839521 [patent_doc_number] => 20210147533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => Methods of Using IL-1beta Compounds [patent_app_type] => utility [patent_app_number] => 16/906118 [patent_app_country] => US [patent_app_date] => 2020-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6084 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16906118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17760038 [patent_doc_number] => 20220233650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => RECOMBINANT FACTOR VIII-FC FOR TREATING HEMOPHILIA AND LOW BONE MINERAL DENSITY [patent_app_type] => utility [patent_app_number] => 17/618808 [patent_app_country] => US [patent_app_date] => 2020-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21845 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -46 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17618808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17483634 [patent_doc_number] => 20220091138 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => Composition for predicting clinical stage of Alzheimer's disease and kit using the same [patent_app_type] => utility [patent_app_number] => 17/425599 [patent_app_country] => US [patent_app_date] => 2020-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6384 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17425599 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20116032 [patent_doc_number] => 12365721 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-22 [patent_title] => Antibody targeting the VP-1 protein, fragments thereof, and uses of same for detecting infection with the BK polyomavirus [patent_app_type] => utility [patent_app_number] => 17/616391 [patent_app_country] => US [patent_app_date] => 2020-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 11 [patent_no_of_words] => 14488 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 514 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20492865 [patent_doc_number] => 12534729 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Uses of synthetic lethal partners for treatment of cancer [patent_app_type] => utility [patent_app_number] => 17/616126 [patent_app_country] => US [patent_app_date] => 2020-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 98 [patent_figures_cnt] => 103 [patent_no_of_words] => 21323 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17865432 [patent_doc_number] => 20220288167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => A STABLE LYOPHILIZED FORMULATION FOR HYBRID FC FUSED G-CSF [patent_app_type] => utility [patent_app_number] => 17/608351 [patent_app_country] => US [patent_app_date] => 2020-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7730 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17608351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16268849 [patent_doc_number] => 20200270336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => STABLE PROTEIN SOLUTION FORMULATION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/871765 [patent_app_country] => US [patent_app_date] => 2020-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16871765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17929834 [patent_doc_number] => 20220324959 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS [patent_app_type] => utility [patent_app_number] => 17/615959 [patent_app_country] => US [patent_app_date] => 2020-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61465 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17615959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18947047 [patent_doc_number] => 11890320 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-06 [patent_title] => CLEC11A is a bone growth agent [patent_app_type] => utility [patent_app_number] => 16/864872 [patent_app_country] => US [patent_app_date] => 2020-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 145 [patent_no_of_words] => 29878 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16236827 [patent_doc_number] => 20200254061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => INJECTABLE BONE MORPHOGENETIC PROTEIN [patent_app_type] => utility [patent_app_number] => 16/863630 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8849 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16863630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16328413 [patent_doc_number] => 20200299379 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => ANTI-IL-17A ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS [patent_app_type] => utility [patent_app_number] => 16/862776 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54109 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 206 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16862776 [rel_patent_id] =>[rel_patent_doc_number] =>)